AMR in the Light of COVID-19
Antimicrobial Resistance Fighter Coalition
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR).
Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world:
- The global movement of microorganisms: Tracking the spread of difficult-to-treat infections (24 September)
- Prevention is stronger than a cure (15 October)
- Aiming in the dark: what happens when disease spreads without diagnosis (5 November)
- Responding to difficult-to-treat infections: Role and responsibilities of governments, researchers, clinicians, industry and patients (19 November)
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.